After-Hours Stock Movers:
Imara Inc. (Nasdaq: IMRA) 22.5% HIGHER; Enliven Therapeutics, Inc., a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, and Imara Inc. (Nasdaq: IMRA) announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
Eargo, Inc. (NASDAQ: EAR) 8.4% LOWER; announced that the record date for its proposed rights offering is October 24, 2022 at 5:00 p.m. Eastern Time (the Record Date).
Travere Therapeutics, Inc. (NASDAQ: TVTX) 5.1% LOWER; announced that following late-cycle review interactions with the U.S. Food and Drug Administration (FDA), the Company expects the previously assigned Prescription Drug User Fee Act (PDUFA) target action date of November 17, 2022 for its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy to be extended by three months.
Amprius Technologies (NYSE: AMPX) 1.6% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $14.00.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。